Feb 22, 2023 / 03:50PM GMT
Ana Berry - Berry Media, Inc. - Moderator
Welcome back, everyone. And next up, we have Trevi Therapeutics that trades on the NASDAQ under the symbol TRVI and is a clinical stage biopharmaceutical company developing the investigational oral therapy, Haduvio, nalbuphine ER, for the treatment of chronic cough in adults with IPF and other chronic cough indications for the treatment of PN. Trevi reported positive results in each of their two lead trials in 2023.
Now, we're introducing three people from the company. We have Jennifer Good, the President, CEO, and Co-Founder of Trevi Therapeutics. Now throughout her career in pharmaceuticals, she's held varying levels of leadership, including CEO, COO, and CFO. Prior to founding Trevi, Jennifer ran a development-stage biotech company, Penwest Pharmaceuticals, which was acquired by its partner. Jennifer is a Board member of Rhythm Pharmaceuticals, Inc.; a Board member of the FARA, a patient advocacy group advancing treatments for the cure of Friedreich's Ataxia; and a Board member of the bio -emerging companies section governing board.
We are
Trevi Therapeutics Inc at Emerging Growth Conference Transcript
Feb 22, 2023
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers